<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The <z:mp ids='MP_0011356'>RAS</z:mp> gene family is among the most studied and best characterized of the known <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>-related genes </plain></SENT>
<SENT sid="1" pm="."><plain>Of the three human ras isoforms, KRAS is the most frequently altered gene, with mutations occurring in 17%-25% of <z:hpo ids='HP_0000001'>all</z:hpo> <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>In particular, approximately 30%-40% of <z:hpo ids='HP_0003003'>colon cancers</z:hpo> harbor a KRAS mutation </plain></SENT>
<SENT sid="3" pm="."><plain>KRAS mutations in <z:hpo ids='HP_0003003'>colon cancers</z:hpo> have been associated with poorer survival and increased <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:hpo ids='HP_0000718'>aggressiveness</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Additionally, KRAS mutations in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> lead to resistance to select treatment strategies </plain></SENT>
<SENT sid="5" pm="."><plain>In this review we examine the history of KRAS, its prognostic value in patients with <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>, and evidence supporting its predictive value in determining appropriate therapies for patients with <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
</text></document>